In this article, we will thoroughly explore the topic of AL-1095 and how it has impacted different aspects of society. From its emergence to its evolution over time, AL-1095 has been the subject of debate and controversy, but it has also been a source of inspiration and change. We will analyze its influence on culture, politics, economics and other areas, as well as its role in the formation of identity and community. Through a multidisciplinary approach, we will examine the various perspectives that exist on AL-1095, seeking to understand its scope and meaning in the current context. Likewise, we will examine whether AL-1095 has a positive or negative impact on society and how it can be understood through different theoretical and methodological approaches. Ultimately, this article aims to provide a complete and balanced view of AL-1095, so that the reader can form an informed opinion on this topic.
![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H22ClNO |
Molar mass | 327.85 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
AL-1095,[1] is a centrally acting stimulant drug with comparable effects to amphetamine,[2] developed by Bristol in the 1970s.[3]
The first-step is a mixed-aldol condensation between 3-quinuclidinone (1) and benzaldehyde (2) gives 2-benzylidene-3-oxoquinuclidine (3). The conjugate addition of the Grignard reagent formed from 4-bromochlorobenzene (4) to the enone gives the benzhydryl (5). MPV reduction of the carbonyl gives the syn stereoisomers, whereas borohydride gave trans. Both diastereoisomers are active but in only one of the enantiomers.